Table 1.

PLK1 inhibitors combined with chemotherapy.

Plk1 Inhibitor	Cancer Type	Chemotherapy drug	Affected process	Affected pathways	Ref.
BI2536	Rhabdomyosarcoma	Eribulin	Cell viability, DNA fragmentation, colony formation, cell cycle	Caspase-3/8/9	[22]
BI2536	Prostate cancer	Nocodazole	Cell viability, cell apoptosis	PARP	[23]
BI2536	Triple-negative breast cancer	Doxorubicin + Cyclophosphamide	Tumor growth	NA	[24]
BI2536	IDH1 mutant gliomas	Temozolomide	Colony formation, tumor growth	CHK1	[25]
BI2536	Gastric cancer cells	Cisplatin	Cell viability, cell invasion, G2/M arrest, cell apoptosis	Cdc25C, Cdc2, CCNB1	[26]
BI2536	Oesophageal squamous cell carcinoma	Cisplatin	Cell apoptosis, cell cycle, colony formation	BAX, Caspase-3, GSDME, H2AX	[27]
BI2536	Neuroblastoma	Vincristine	DNA fragmentation, colony formation, cell cycle	BAX/BAK, BCL2, MCL1, Caspase-9	[28]
BI2536	Squamous cell carcinoma	Cpt11	Cell apoptosis, tumor growth	PARP, Caspase-3	[29]
BI6727	Cervical cancer	Cisplatin	Cell proliferation, tumor growth	NA	[30]
BI6727	Rhabdomyosarcoma	Vincristine	Cell viability	NA	[31]
BI6727	Thyroid cancer	Sorafenib	Tumor growth	NA	[32]
BI6727	Ovarian cancer	Paclitaxel	Cell apoptosis, cell cycle, colony formation	BCL2, Caspase-3, BAK	[33]
BI6727	Acute myeloid leukemia	Azacitidine	Cell viability	NA	[34]
BI6727	Ewing sarcoma	Eribulin	DNA fragmentation, cell viability, cell cycle	BCL2, BAX, MCL1	[35]
NMS-1286937	Triple-negative breast cancer	Paclitaxel	Cell proliferation	NA	[36]
NMS-1286937	Mucinous ovarian carcinoma	Paclitaxel	Cell viability, cell cycle, tumor growth	Caspase-3, H2AX	[37]
NMS-1286937	Leukemia, colon cancer	Cytarabine/irinotecan	Tumor growth	NA	[38]
NMS-1286937	Osteosarcoma	Doxorubicin	Cell cycle	NA	[39]
TAK-960	Colorectal cancer	Irinotecan	Tumor growth	NA	[40]
GSK461364	Pancreatic cancer	Gemcitabine	Tumor growth	Ki-67	[41]
GSK461364	Osteosarcoma	Paclitaxel	Cell viability	NA	[42]
Genistein	Paclitaxel-resistant prostate cancer	Bicalutamide	Cell viability	NA	[43]